287 related articles for article (PubMed ID: 32163218)
1. Curcumin β-D-glucuronide exhibits anti-tumor effects on oxaliplatin-resistant colon cancer with less toxicity in vivo.
Ozawa-Umeta H; Kishimoto A; Imaizumi A; Hashimoto T; Asakura T; Kakeya H; Kanai M
Cancer Sci; 2020 May; 111(5):1785-1793. PubMed ID: 32163218
[TBL] [Abstract][Full Text] [Related]
2. Curcumin β-D-Glucuronide Plays an Important Role to Keep High Levels of Free-Form Curcumin in the Blood.
Ozawa H; Imaizumi A; Sumi Y; Hashimoto T; Kanai M; Makino Y; Tsuda T; Takahashi N; Kakeya H
Biol Pharm Bull; 2017; 40(9):1515-1524. PubMed ID: 28867734
[TBL] [Abstract][Full Text] [Related]
3. GOLPH3 inhibition reverses oxaliplatin resistance of colon cancer cells via suppression of PI3K/AKT/mTOR pathway.
Yu T; An Q; Cao XL; Yang H; Cui J; Li ZJ; Xiao G
Life Sci; 2020 Nov; 260():118294. PubMed ID: 32818544
[TBL] [Abstract][Full Text] [Related]
4. BAY61-3606 potentiates the anti-tumor effects of TRAIL against colon cancer through up-regulating DR4 and down-regulating NF-κB.
Du J; Wang Y; Chen D; Ji G; Ma Q; Liao S; Zheng Y; Zhang J; Hou Y
Cancer Lett; 2016 Dec; 383(2):145-153. PubMed ID: 27721019
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic characterization of TBP1901, a prodrug form of aglycone curcumin, and CRISPR-Cas9 screen for therapeutic targets of aglycone curcumin.
Abe T; Horisawa Y; Kikuchi O; Ozawa-Umeta H; Kishimoto A; Katsuura Y; Imaizumi A; Hashimoto T; Shirakawa K; Takaori-Kondo A; Yusa K; Asakura T; Kakeya H; Kanai M
Eur J Pharmacol; 2022 Nov; 935():175321. PubMed ID: 36228744
[TBL] [Abstract][Full Text] [Related]
6. Chemopreventive efficacy of oral curcumin: a prodrug hypothesis.
Liu G; Khanna V; Kirtane A; Grill A; Panyam J
FASEB J; 2019 Aug; 33(8):9453-9465. PubMed ID: 31136203
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and Antitumor Properties of BQC-Glucuronide, a Camptothecin Prodrug for Selective Tumor Activation.
Prijovich ZM; Burnouf PA; Chou HC; Huang PT; Chen KC; Cheng TL; Leu YL; Roffler SR
Mol Pharm; 2016 Apr; 13(4):1242-50. PubMed ID: 26824303
[TBL] [Abstract][Full Text] [Related]
8. The tyrosine phosphatase SHP2 promotes proliferation and oxaliplatin resistance of colon cancer cells through AKT and ERK.
Yu M; Xu C; Zhang H; Lun J; Wang L; Zhang G; Fang J
Biochem Biophys Res Commun; 2021 Jul; 563():1-7. PubMed ID: 34052504
[TBL] [Abstract][Full Text] [Related]
9. Selective cancer therapy by extracellular activation of a highly potent glycosidic duocarmycin analogue.
Chen KC; Schmuck K; Tietze LF; Roffler SR
Mol Pharm; 2013 May; 10(5):1773-82. PubMed ID: 23448264
[TBL] [Abstract][Full Text] [Related]
10. Metformin revert insulin-induced oxaliplatin resistance by activating mitochondrial apoptosis pathway in human colon cancer HCT116 cells.
Liu C; Liu Q; Yan A; Chang H; Ding Y; Tao J; Qiao C
Cancer Med; 2020 Jun; 9(11):3875-3884. PubMed ID: 32248666
[TBL] [Abstract][Full Text] [Related]
11. MyD88 in DNA repair and cancer cell resistance to genotoxic drugs.
Kfoury A; Le Corf K; El Sabeh R; Journeaux A; Badran B; Hussein N; Lebecque S; Manié S; Renno T; Coste I
J Natl Cancer Inst; 2013 Jul; 105(13):937-46. PubMed ID: 23766530
[TBL] [Abstract][Full Text] [Related]
12. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
[TBL] [Abstract][Full Text] [Related]
13. Combined anti-cancer effects of curcumin and oxaliplatin on colon carcinoma colo205 cells using transplanted nude mice.
Zhang N; Hao Y; Liu H; Yu Q; Bo B; Liang J
Pak J Pharm Sci; 2021 Sep; 34(5(Special)):2021-2025. PubMed ID: 34862868
[TBL] [Abstract][Full Text] [Related]
14. Curcumin potentiates the antitumor effects of 5-FU in treatment of esophageal squamous carcinoma cells through downregulating the activation of NF-κB signaling pathway in vitro and in vivo.
Tian F; Fan T; Zhang Y; Jiang Y; Zhang X
Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):847-55. PubMed ID: 23017833
[TBL] [Abstract][Full Text] [Related]
15. Curcumin ameliorates oxaliplatin-induced chemoresistance in HCT116 colorectal cancer cells in vitro and in vivo.
Howells LM; Sale S; Sriramareddy SN; Irving GR; Jones DJ; Ottley CJ; Pearson DG; Mann CD; Manson MM; Berry DP; Gescher A; Steward WP; Brown K
Int J Cancer; 2011 Jul; 129(2):476-86. PubMed ID: 20839263
[TBL] [Abstract][Full Text] [Related]
16. C086, a novel analog of curcumin, induces growth inhibition and down-regulation of NFκB in colon cancer cells and xenograft tumors.
Chen C; Liu Y; Chen Y; Xu J
Cancer Biol Ther; 2011 Nov; 12(9):797-807. PubMed ID: 21900746
[TBL] [Abstract][Full Text] [Related]
17. A new herbal formula BP10A exerted an antitumor effect and enhanced anticancer effect of irinotecan and oxaliplatin in the colon cancer PDTX model.
Kim J; Kim HY; Hong S; Shin S; Kim YA; Kim NS; Bang OS
Biomed Pharmacother; 2019 Aug; 116():108987. PubMed ID: 31112870
[TBL] [Abstract][Full Text] [Related]
18. Novel synthetic curcumin analogs as potent antiangiogenic agents in colorectal cancer.
Rajitha B; Nagaraju GP; Shaib WL; Alese OB; Snyder JP; Shoji M; Pattnaik S; Alam A; El-Rayes BF
Mol Carcinog; 2017 Jan; 56(1):288-299. PubMed ID: 27128654
[TBL] [Abstract][Full Text] [Related]
19. Curcumin synergizes with resveratrol to inhibit colon cancer.
Majumdar AP; Banerjee S; Nautiyal J; Patel BB; Patel V; Du J; Yu Y; Elliott AA; Levi E; Sarkar FH
Nutr Cancer; 2009; 61(4):544-53. PubMed ID: 19838927
[TBL] [Abstract][Full Text] [Related]
20. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice.
Aggarwal BB; Shishodia S; Takada Y; Banerjee S; Newman RA; Bueso-Ramos CE; Price JE
Clin Cancer Res; 2005 Oct; 11(20):7490-8. PubMed ID: 16243823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
